Guang Peng

8.2k citations

79 papers · 4.5k indexed · 2 hit papers · h-index 33

Oncology top 1%
- PARP inhibition in cancer therapy 23
- Cancer-related Molecular Pathways 14
Cancer Research top 2%
- Cancer Genomics and Diagnostics 6
Molecular Biology top 2%
- DNA Repair Mechanisms 32
- CRISPR and Genetic Engineering 12
- Chromatin Remodeling and Cancer 9
- Genomics and Chromatin Dynamics 7
Pathology and Forensic Medicine top 2%
- Cancer Mechanisms and Therapy 9
Reproductive Medicine top 5%

Co-authors: Shiaw‐Yih Lin Gordon B. Mills Yang Peng Zhenlin Ju Jianfeng Shen Hui Dai Timothy A. Yap Mei‐Ren Pan
Cited by: Oncology Cancer Research Molecular Biology
Journals: Nature (1 paper)Science (1 paper)Proceedings of the National Academy of Sciences (1 paper)
Partner nations: United States China Taiwan

In The Last Decade

Guang Peng

78 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Guang Peng

Since Specialization

Citations

This map shows the geographic impact of Guang Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guang Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guang Peng more than expected).

Fields of papers citing papers by Guang Peng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guang Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guang Peng. The network helps show where Guang Peng may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Guang Peng, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Guang Peng Line = papers co-authored together Guang Peng links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Non-enzymatic protein targeting agents as a promising strategy for cancer treatment SHILAP Revista de lepidopterología ·M. Ambrose,Jin‐Hyung Lee,Aleem Syed,Zamal Ahmed,Guang Peng	2025	1
2	SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma Clinical Cancer Research ·Xian-De Liu,Yanting Zhang,Daniel J. McGrail,X. Zhang,Truong Lam,Anh Hoang,Elshad Hasanov,Ganiraju C. Manyam,Christine B. Peterson,Haifeng Zhu,Shwetha V. Kumar,Rehan Akbani,Patrick G. Pilié,Nizar M. Tannir,Guang Peng,Eric Jonasch	2023	8
3	PPP1R7 Is a Novel Translocation Partner of CBFB via t(2;16)(q37;q22) in Acute Myeloid Leukemia Genes ·Lulu Wang,Wei Wang,Hannah C. Beird,Xueqian Cheng,Hong Fang,Guilin Tang,Gökçe Törüner,C. Cameron Yin,Min You,Ghayas C. Issa,Gautam Borthakur,Guang Peng,Joseph D. Khoury,L. Jeffrey Medeiros,Zhenya Tang	2022	0
4	ATR Inhibition Induces CDK1–SPOP Signaling and Enhances Anti–PD-L1 Cytotoxicity in Prostate Cancer Clinical Cancer Research ·Zhe Tang,Patrick G. Pilié,Chuandong Geng,Ganiraju C. Manyam,Guang Yang,Sanghee Park,Daoqi Wang,Shan Peng,Cheng Wu,Guang Peng,Timothy A. Yap,Paul G. Corn,Bradley M. Broom,Timothy C. Thompson	2021	97
5	MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors Cancer Research ·Bin Yang,Xi Li,Yu Fu,Ensong Guo,Youqiong Ye,Fuxia Li,Si Liu,Rourou Xiao,Chen Liu,Funian Lu,Jia Huang,Tianyu Qin,Leng Han,Guang Peng,Gordon B. Mills,Chaoyang Sun,Gang Chen	2021	38
6	ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application Cancer Letters ·Guangyuan Hu,Wei Tu,Yang Liu,(unknown),Guang Peng,(unknown),(unknown)	2020	38
7	The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer Molecular Cancer Therapeutics ·Yuping Yin,Weizhen Liu,Qian Shen,Peng Zhang,Lulu Wang,Ruikang Tao,Hang Li,Xianxiong Ma,Xiangyu Zeng,Jae‐Ho Cheong,Shumei Song,Jaffer A. Ajani,Gordon B. Mills,Kaixiong Tao,Guang Peng	2019	16
8	PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAnessbreakdown → Cancer Research ·Jianfeng Shen,Wei Zhao,Zhenlin Ju,Lulu Wang,Yang Peng,Marilyne Labrie,Timothy A. Yap,Gordon B. Mills,Guang Peng	2018	427
9	ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage response Nucleic Acids Research ·Lufen Chang,Lien Fan Shen,Hu Zhou,Jing Gao,Hangyi Pan,Li Zheng,Brian Armstrong,Yang Peng,Guang Peng,Binhua P. Zhou,Steven T. Rosen,Binghui Shen	2018	18
10	APOBEC3B, a molecular driver of mutagenesis in human cancers Cell & Bioscience ·Jun Zou,Chen Wang,Xiangyi Ma,Eddie C. Y. Wang,Guang Peng	2017	59
11	Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers Science Translational Medicine ·Chaoyang Sun,Yong Fang,Jun‐Jie Yin,Jian Chen,Zhenlin Ju,Dong Zhang,Xiaohua Chen,Christopher P. Vellano,Kang Jin Jeong,Patrick Kwok‐Shing Ng,Agda Karina Eterovic,Neil E. Bhola,Yiling Lu,Shannon N. Westin,Jennifer R. Grandis,Shiaw‐Yih Lin,Kenneth L. Scott,Guang Peng,Joan S. Brugge,Gordon B. Mills	2017	170
12	Anti-rheumatic drug iguratimod (T-614) alleviates cancer-induced bone destruction via down-regulating interleukin-6 production in a nuclear factor-κB-dependent manner Journal of Huazhong University of Science and Technology [Medical Sciences] ·Yue Sun,Da-wei Ye,Peng Zhang,Ying-xing Wu,Bang-yan Wang,Guang Peng,Shiying Yu	2016	11
13	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer Clinical Cancer Research ·Wei Mo,Qingxin Liu,Curtis Chun-Jen Lin,Hui Dai,Yang Peng,Yulong Liang,Guang Peng,Funda Meric‐Bernstam,Gordon B. Mills,Kaiyi Li,Shiaw‐Yih Lin	2015	90
14	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitorsbreakdown → Cancer Discovery ·Jianfeng Shen,Yang Peng,Leizhen Wei,Wei Zhang,Lin Yang,Li Lan,Prabodh Kapoor,Zhenlin Ju,Qianxing Mo,Ie‐Ming Shih,Iván P. Uray,Xiangwei Wu,Powel H. Brown,(unknown),Gordon B. Mills,Guang Peng	2015	358
15	TUSC4 Functions as a Tumor Suppressor by Regulating BRCA1 Stability Cancer Research ·Yang Peng,Hui Dai,Wenge Wang,Curtis Chun-Jen Lin,Wei Mo,Guang Peng,Shiaw‐Yih Lin	2014	26
16	BRIT1 regulates p53 stability and functions as a tumor suppressor in breast cancer Carcinogenesis ·Bo Zhang,Wenge Wang,Hui Dai,Ruozhen Hu,Yulong Liang,Kaiyi Li,Guobin Wang,Guang Peng,Shiaw‐Yih Lin	2013	13
17	Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection Cancer Research ·Guang Peng,Hui Dai,Wei Zhang,Hui-Ju Hsieh,Mei‐Ren Pan,Yun‐Yong Park,Robert Y. L. Tsai,Isabelle Bedrosian,Ju‐Seog Lee,Grzegorz Ira,Shiaw‐Yih Lin	2012	64
18	Loss of Function of the Tumor Suppressor DKC1 Perturbs p27 Translation Control and Contributes to Pituitary Tumorigenesis Cancer Research ·Cristian Bellodi,Olya Krasnykh,Nikesha Haynes,Marily Theodoropoulou,Guang Peng,Lorenzo Montanaro,Davide Ruggero	2010	132
19	Rak Functions as a Tumor Suppressor by Regulating PTEN Protein Stability and Function Cancer Cell ·Eun-Kyoung Yim,Guang Peng,Hui Dai,Ruozhen Hu,Kaiyi Li,Yiling Lu,Gordon B. Mills,Funda Meric‐Bernstam,Bryan T. Hennessy,Rolf J. Craven,Shiaw‐Yih Lin	2009	152
20	Impaired Control of IRES-Mediated Translation in X-Linked Dyskeratosis Congenita Science ·Andrew Yoon,Guang Peng,Yves Brandenburg,Ornella Zollo,Wei Xu,Eduardo Magalhães Rego,Davide Ruggero	2006	334

About Guang Peng

Guang Peng is a scholar working on Oncology, Cancer Research and Molecular Biology, having authored 79 papers that have together received 4.5k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (32 papers), PARP inhibition in cancer therapy (23 papers), Cancer-related Molecular Pathways (14 papers), CRISPR and Genetic Engineering (12 papers), Chromatin Remodeling and Cancer (9 papers), Cancer Mechanisms and Therapy (9 papers), Genomics and Chromatin Dynamics (7 papers) and Cancer Genomics and Diagnostics (6 papers). The work is most often cited by research in Oncology (1.7k citations), Cancer Research (823 citations) and Molecular Biology (3.4k citations). Guang Peng has collaborated with scholars based in United States, China and Taiwan. Frequent co-authors include Shiaw‐Yih Lin, Gordon B. Mills, Yang Peng, Zhenlin Ju, Jianfeng Shen, Hui Dai, Timothy A. Yap, Mei‐Ren Pan, Kaiyi Li and Davide Ruggero. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact